Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Prelude Therapeutics Inc (PRLD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
4
| Huang Jane (President, CMO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Exercised 9,375 restricted stock units
@ $0 |
|
| 07/06/2023 |
4
| Huang Jane (President, CMO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Paid exercise price by delivering 3,242 shares
@ $4.65, valued at
$15.1k
Exercised 9,375 restricted stock units
@ $0 |
|
| 05/26/2023 |
4
| Vaddi Krishna (CEO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 1,000 shares
@ $5.0114, valued at
$5k
Bought 900 shares
@ $5.31, valued at
$4.8k
|
|
| 05/25/2023 |
4
| Lim Bryant David (Chief Legal Officer, Corp Sec.) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 2,400 shares
@ $5.39, valued at
$12.9k
|
|
| 05/25/2023 |
4
| Chardonnet Laurent (CFO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 5,000 shares
@ $5.5, valued at
$27.5k
|
|
| 05/25/2023 |
4
| Vaddi Krishna (CEO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 11,856 shares
@ $5.63, valued at
$66.7k
|
|
| 05/24/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 869,565 shares
@ $5.75, valued at
$5M
|
|
| 05/24/2023 |
4
| Bonita David P (10% Owner) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 869,565 shares
@ $5.75, valued at
$5M
|
|
| 05/24/2023 |
4
| BAKER BROS. ADVISORS LP (10% Owner) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 121,178 options to buy
@ $5.75, valued at
$696.8k
Granted 1,327,044 options to buy
@ $5.75, valued at
$7.6M
Granted 970,220 options to buy
@ $0.0001, valued at
$97
Granted 10,625,036 options to buy
@ $0.0001, valued at
$1.1k
|
|
| 03/02/2023 |
4
| Lim Bryant David (Chief Legal Officer, Corp Sec.) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 250,000 options to buy
@ $5.93, valued at
$1.5M
|
|
| 02/09/2023 |
4
| Scherle Peggy (Chief Scientific Officer) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 135,000 options to buy
@ $7.2, valued at
$972k
|
|
| 02/09/2023 |
4
| Combs Andrew (EVP, Head of Chemistry) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 135,000 options to buy
@ $7.2, valued at
$972k
|
|
| 02/09/2023 |
4
| Chardonnet Laurent (CFO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 135,000 options to buy
@ $7.2, valued at
$972k
|
|
| 02/09/2023 |
4
| Huang Jane (President, CMO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 150,000 options to buy
@ $7.2, valued at
$1.1M
|
|
| 02/09/2023 |
4
| Vaddi Krishna (CEO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 330,000 options to buy
@ $7.2, valued at
$2.4M
|
|
| 12/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/04/2022 |
4
| Huang Jane (President, CMO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 460,000 options to buy
@ $4.86, valued at
$2.2M
Granted 150,000 restricted stock units
@ $0 |
|
| 04/04/2022 |
4
| Combs Andrew (EVP, Head of Chemistry) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Exercised 36,062 shares
@ $1.89, valued at
$68.2k
Exercised 36,062 options to buy
@ $1.89, valued at
$68.2k
|
|
| 03/22/2022 |
4
| Chardonnet Laurent (CFO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 6,500 shares
@ $7.51, valued at
$48.8k
|
|
| 02/17/2022 |
4
| Scherle Peggy (Chief Scientific Officer) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 100,000 options to buy
@ $10.58, valued at
$1.1M
|
|
| 02/17/2022 |
4
| Chardonnet Laurent (CFO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 90,000 options to buy
@ $10.58, valued at
$952.2k
|
|
| 02/17/2022 |
4
| Vaddi Krishna (CEO) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 327,900 options to buy
@ $10.58, valued at
$3.5M
|
|
| 02/17/2022 |
4
| Morosini Deborah (EVP, Chief of Clinical Affairs) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 90,000 options to buy
@ $10.58, valued at
$952.2k
|
|
| 02/17/2022 |
4
| Combs Andrew (EVP, Head of Chemistry) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 100,000 options to buy
@ $10.58, valued at
$1.1M
|
|
| 01/05/2022 |
4
| Sandor Victor (Director) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 11,206 options to buy
@ $13.22, valued at
$148.1k
|
|
|
|
|